NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, took a closer look at "one of my favorite" speculation plays with GW Pharmaceuticals (GWPH).
The company recently had its cannabinoid treatment for a rare case of epilepsy in children "fast-tracked" by the Food and Drug Administration.
Cramer said he sees this as the FDA saying that there are many reasons to start thinking of marijuana as an important and legitimate treatment for the side effects resulting from many illnesses.
"GW Pharmaceuticals has been the play" on marijuana treatment, he reasoned.
It is a British company and can therefore work with marijuana, something many U.S. pharmaceutical companies wish they could do as well.
"Watch GWPH," Cramer concluded, "it's going higher."
-- Written by Bret Kenwell in Petoskey, Mich.